尿液核基质蛋白22联合膀胱肿瘤抗原检测对膀胱癌的诊断价值  

Diagnostic value of urinary nuclear matrix protein 22 combined with bladder tumor antigen detection for bladder cancer

作　　者：杨婧 索杰[2] 高海锋[3] Yang Jing;Suo Jie;Gao Haifeng(Department of Laboratory Medicine,Jinduicheng Hospital,Shaanxi Healthcare Group Co.Ltd.,Weinan 714102,China;Department of Urology,Baoji Central Hospital in Shaanxi Province,Baoji 721008,China;Department of Laboratory Medicine,Baoji Central Hospital in Shaanxi Province,Baoji 721008,China)

机构地区：[1]陕西省健康医疗集团有限公司金堆城医院检验科,陕西渭南714102 [2]陕西省宝鸡市中心医院泌尿外科,721008 [3]陕西省宝鸡市中心医院检验科,721008

出　　处：《肿瘤研究与临床》2020年第11期772-775,共4页Cancer Research and Clinic

摘　　要：目的:探讨尿液核基质蛋白22(NMP22)联合膀胱肿瘤抗原(BTA)检测在膀胱癌诊断中的价值,为膀胱癌的早期筛查提供实验室依据。方法:回顾性分析2018年8月至2019年7月陕西省宝鸡市中心医院收治的315例疑似膀胱癌患者的临床病理资料,其中经手术病理或膀胱镜活组织检查确诊为膀胱癌248例,泌尿系统良性疾病67例;同时选择同期体检健康者100名作为健康对照组。采用酶联免疫吸附试验(ELISA)检测尿液NMP22和BTA水平。结果:膀胱癌组、泌尿系统良性疾病组和健康对照组尿液NMP22表达水平分别为(28.4±8.8)ng/ml、(12.7±3.0)ng/ml、(4.3±1.5)ng/ml,差异具有统计学意义( F=26.41, P<0.05);BTA表达水平分别为(25.1±8.1)ng/ml、(10.4±2.9)ng/ml、(6.4±2.4)ng/ml,差异具有统计学意义( F=23.62, P<0.05)。不同TNM分期、病理分级的膀胱癌患者尿液NMP22和BTA表达水平比较,差异均具有统计学意义(均 P<0.05)。尿液NMP22和BTA联合检测的受试者工作特征曲线下面积、灵敏度、阴性预测值分别为0.895、96.98%和61.11%,均高于其单项检测,差异均具有统计学意义(均 P<0.05)。NMP22和BTA诊断膀胱癌的cut-off值分别为32.42 ng/ml和29.13 ng/ml。 结论:尿液NMP22和BTA联合检测对膀胱癌诊断具有较高的临床价值,检测具有简便、快速、无创、批量筛查等优点,值得在临床上推广。Objective To investigate the diagnostic value of urinary nuclear matrix protein 22(NMP22)combined with bladder tumor antigen(BTA)detection for bladder cancer,in order to provide a laboratory basis for early screening of bladder cancer.Methods The clinicopathological data of 315 suspected bladder cancer patients in Baoji Central Hospital in Shaanxi Province from August 2018 to July 2019 were retrospectively analyzed.Among the patients,248 patients with bladder cancer and 67 patients with urological benign disease were diagnosed by surgical pathology or cystoscope biopsy,and 100 healthy people that took the normal physical examination in the same period were selected as healthy control group.The levels of urinary NMP22 and BTA were detected by enzyme-linked immunosorbent assay(ELISA).Results The expression levels of urinary NMP22 in the bladder cancer group,urological benign disease group and healthy control group were(28.4±8.8)ng/ml,(12.7±3.0)ng/ml and(4.3±1.5)ng/ml,and the difference was statistically significant(F=26.41,P<0.05);BTA expression levels were(25.1±8.1)ng/ml,(10.4±2.9)ng/ml and(6.4±2.4)ng/ml,and the difference was statistically significant(F=23.62,P<0.05).The differences in the expression levels of urinary NMP22 and BTA in bladder cancer patients with different TNM stages and pathological grades were statistically significant(all P<0.05).The area under the receiver operating characteristic curve,sensitivity,and negative predictive value of the combined detection of urinary NMP22 and BTA were 0.895,96.98%,and 61.11%,respectively,which were higher than the single detection,and the differences were statistically significant(all P<0.05).The cut-off values of urinary NMP22 and BTA for diagnosis of bladder cancer were 32.42 ng/ml and 29.13 ng/ml,respectively.Conclusions The combined detection of urinary NMP22 and BTA has a high clinical value for the diagnosis of bladder cancer.The detection has the advantages of simple,rapid,non-invasive,and mass screening,which is worthy of clinical promotion.

关 键 词：膀胱肿瘤 核基质蛋白22 膀胱肿瘤抗原 尿 

分 类 号：R737.14[医药卫生—肿瘤]